Phase I Evaluation of Gemcitabine, Cisplatin and Low Dose Continuous Infusion 5-Fluorouracil in Patients with Advanced Malignancies
Phase I, Lilly Research Laboratories, KMCRI # 5/99, Activated 9/20/99

Eligibility Requirements:


Disease Characteristics

Locally advanced or metastatic carcinoma of the head and neck, esophagus, ovaries, non-small cell and small cell lung or breast or an advanced malignancy for which no effective therapy exists

Evaluable or measurable disease

Not curable by surgery


Prior/Concurrent Therapy

No more than one prior chemotherapy regimen. If more than one, must discuss with Principal Investigator.

No prior gemcitabine, cisplatin or continuous 5-FU

Prior radiation allowed if at least 4 weeks has lapsed since treatment

One prior biologic response modifier okay

No concurrent hormonal, radiotherapy, immunotherapy or chemotherapy


Patient Characteristics

Life expectancy of at least 8 weeks


Carlos Rubin de Celis, M.D., and Stephen Williamson, M.D., are the Principal Investigators for this study. Please contact Nancy Johnson, R.N., (913) 588-4700, or Ruth Vinyard, R.N., (913) 588-4700, for more information or for patient registration.